Among the available phase II trials, the EMERGING-CTONG 1103 randomized erlotinib vs. gemcitabine plus cisplatin (GC chemotherapy) as neoadjuvant therapy in stage IIIAN2 NSCLC harboring an EGFR mutation in exon 19 or 21. This evidence concerns the gene EGFR and non-small cell lung carcinoma.